Neonatal/infantile epilepsy syndrome

This phase 3 trial tests whether soticlestat can reduce seizures in people with Dravet syndrome or Lennox-Gastaut syndrome who have already used fenfluramine. Participants take soticlestat as tablets or mini-tablets, and researchers measure changes in seizure frequency over the f…

This study looked at the long-term safety of soticlestat when added to standard seizure medicines for people with Dravet syndrome or Lennox-Gastaut syndrome. It included 352 children and adults who had already been in earlier studies. The trial was terminated early, so results ar…

This study looked at the long-term safety of soticlestat, an experimental drug, in children and adults with severe forms of epilepsy like Dravet syndrome and Lennox-Gastaut syndrome. Participants took soticlestat twice a day along with their usual seizure medicines. The study was…

This study tested the drug fenfluramine (FINTEPLA) in adults with Dravet syndrome whose seizures were not controlled by other medications. The trial was open-label and added fenfluramine to existing treatments. It aimed to see if the drug could reduce monthly seizures by at least…

This study tested whether lorcaserin, when added to current medications, could reduce convulsive seizures in people with Dravet syndrome, a severe form of epilepsy. The trial planned to enroll about 22 participants aged 2 and older, but it was terminated early. The main goal was …

This trial tests whether giving a low dose of the hormone ACTH to infants with early warning signs on their brain wave test (EEG) can prevent West syndrome, a severe form of epilepsy. Infants between 2 and 12 months old who show a specific pre-seizure brain pattern are treated wi…

This study tested a cannabidiol (CBD) oral solution in children under 2 years old with tuberous sclerosis complex, Dravet syndrome, or Lennox-Gastaut syndrome who had uncontrolled seizures. The goal was to see if CBD is safe and can reduce seizures. However, the study was termina…